COMP <GO>

APVO vs SBFM // FORWARD P/E MULTIPLE

Aptevo Therapeutics Inc. (NASDAQ) VS. Sunshine Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: APVO 0 — SBFM 4

■ METRIC PARITY

LAST: $1.36 (+4.62%) • MKT CAP: $2.5M

forward-pe

—

LAST: $3.33 (+7.07%) • MKT CAP: $2.5M

forward-pe

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APVO VS. SBFM) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	APVO	SBFM	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	33.80%	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	-21.40%	-13.60	SBFM	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	—	—	—	TIE	/fcf-yield <GO>
Operating Margin	—	-17.20%	—	TIE	/operating-margins <GO>
Net Profit Margin	—	-16.50%	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	4.10%	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	0.20	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	2/9	4/9	-2.00	SBFM	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	26.9	27.3	-0.45	SBFM	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple ACTIVE	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$2.5M	$2.5M	-$83.4K	SBFM	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	APVO REV	SBFM REV	APVO GROSS %	SBFM GROSS %	APVO FCF	SBFM FCF
FY 2025	$0	$36.3M	—	33.8%	-$25.6M	-$5.5M
FY 2024	$0	$34.9M	—	30.6%	-$23.8M	-$14.2M
FY 2023	$0	$24.1M	—	—	-$11.7M	-$8.8M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

APVO // BETA —

SBFM // BETA —